Bixiye
P1-17 Prior Authorization Requirement for Gender Dysphoria
Taariikhda uu dhaqangalayo Barnaamijka: Jan 18, 2017
Natiijooyinka Raadinta
Soo bandhiga 3161 - 3170 ee natiijooyinka 4919
Bixiye
P44-16 Addition of a Drug (Viekira XR) to the Hepatitis C Second Generation Prior Authorization with Quantity Limit Program
Taariikhda uu Dhaqangalayo Barnaamijka: Sep 01, 2016
Bixiye
P36-16 Case Management (T1016) Billing for Tuberculosis Related Services for Government Programs Subscribers
Taariikhda dhaqangalka Barnaamijka: Jul 27, 2016
Bixiye
P60-16 New Drug-Related Prior Authorization Criteria with Quanatity Limit for Topical Diclofenac Gel, Fluorourcil Cream, Imquimod Cream and Ingenol Gel
Taariikhda uu dhaqangalayo Barnaamijka: Des 13, 2016
Bixiye
P39-16 Expansion of Drug-Related Xenazine Prior Authorization Criteria with Quantity Limit to Minnesota Health Care Programs
Taariikhda barnaamijka Dhaqangalayso Agosto 03, 2016
Bixiye
P40-16 New Drug-Related Prior Authorization Criteria with Quantity Limit for Lidocaine Transdermal
Taariikhda barnaamijka Dhaqangalayso Agosto 03, 2016
Bixiye
P45R1-16 Update on New Drug, Ocrevus (ocrelizumab)
Taariikhda uu dhaqangalayo Barnaamijka: Des 05, 2016
Bixiye
P57-16 Change in Medical Policy and Commercial Benefit Coverage of CT Colonography Colorectal Cancer Screening Test
Taariikhda uu dhaqangalayo Barnaamijka: Nov 22, 2016
Bixiye
P45-16 A New Drug, Ocrevus (ocrelizumab) Will Require Prior Authorization
Taariikhda uu dhaqangalayo Barnaamijka: Des 05, 2016
Bixiye
P37-16 Addition of a Drug (Epclusa) to the Hepatitis C Second Generation Prior Authorization with Quantity Limit Program
Taariikhda barnaamijka Dhaqangalayso Agosto 03, 2016